Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02916745 · ClinicalTrials.gov registry record · Phase 1

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis, sponsored by Concordia Laboratories.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
7
Study locations

NCT02916745 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis that has completed, run by Concordia Laboratories. The registered enrollment target is 5 participants, below the 289-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02916745, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Lung Metastasis, has completed, sponsored by Concordia Laboratories.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
7
Study locations

Study Summary

This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Canada. Participation will last 6 months.

Conditions Studied

Non-small Cell Lung Cancer (NSCLC) Lung Metastasis

Interventions

  • DRUG Porfimer sodium
  • DEVICE Fiber optic

Study Locations (7)

Florida

  • University of Florida - Gainesville

Georgia

  • Southeastern Regional Medical Center - Atlanta

Illinois

  • Alexian Brothers Hospital Network - Elk Grove Village

Oklahoma

  • Southwestern Regional Medical Center - Tulsa

Washington

  • Providence Medical Research Center - Spokane

Wisconsin

  • University of Wisconsin-Madison - Madison

Ontario

  • Toronto General Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2017-01-26
Est. Completion 2019-04-12
Phase Phase 1

Sponsor

Concordia Laboratories

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02916745

The ClinicalTrials.gov registry entry for NCT02916745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 289-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (98% lower). The listed sponsor is Concordia Laboratories, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Porfimer sodium is the first listed.

NCT02916745 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Florida, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT02916745 about?

NCT02916745 is a clinical study titled "Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer". This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery. It will involve 10 sites in USA and Cana...

What is the current status of trial NCT02916745?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-01-26. Estimated completion is 2019-04-12.

What conditions does trial NCT02916745 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Lung Metastasis.

What interventions are being tested in trial NCT02916745?

The interventions under investigation include: Porfimer sodium (DRUG), Fiber optic (DEVICE).

Who is sponsoring clinical trial NCT02916745?

This trial is sponsored by Concordia Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02916745 being conducted?

This trial has 7 study locations across Florida, Georgia, Illinois, Oklahoma, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

Lung Metastasis

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.